AstraZeneca PLC AstraZeneca increases 2024 dividend by 7%
11 Avril 2024 - 8:00AM
RNS Regulatory News
RNS Number : 1111K
AstraZeneca PLC
11 April 2024
11 April 2024
AstraZeneca increases 2024 dividend by
7%
AstraZeneca announced today that the Board intends to increase the annualised dividend for 2024
by $0.20 to $3.10 per share, underlining the company's confidence in its performance and
cash generation. This takes into account other capital
allocation priorities as well as previously announced acquisitions
and business development.
Michel Demaré, Chair, AstraZeneca said: "The
Board is delighted to announce a 7% increase to the dividend,
taking it to $3.10 per share. This uplift is in line with our
progressive dividend policy, which remains unchanged, and reflects
the continuing strength of AstraZeneca's investment proposition for
shareholders."
No changes are planned to the Company's normal
dividend payment timetable, which is:
·
First interim dividend - announced with half-year results and
paid in September.
·
Second interim dividend - announced with full-year results
and paid in March.
The Board also reaffirms its commitment to
AstraZeneca's progressive dividend policy.
Notes
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and follow
the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DIVDZGMDLGVGDZM
Astrazeneca (LSE:AZN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Astrazeneca (LSE:AZN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024